A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction

Trial Profile

A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2018

At a glance

  • Drugs Rivoceranib (Primary) ; Capecitabine; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jan 2018 Planned number of patients changed from 40 to 48.
    • 14 Jan 2018 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
    • 14 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top